News

News

Newsarrivo_admin2024-11-05T20:17:42+00:00

Press Releases

ArrivoBio Raises $45M in Series B Financing to Advance Pipeline
Arrivo BioVentures Emerges from Stealth Mode with a Robust Pipeline and Promising Data
Serial BioPharma Entrepreneurial Team Launches Arrivo BioVentures with $49 Million in Committed Funding
Arrivo BioVentures Closes Enrollment in Large Phase 2 Clinical Trial for Major Depressive Disorder
Arrivo BioVentures Announces SP-624 Demonstrated Robust Efficacy in Females With Major Depressive Disorder in Phase 2 Study
Psychiatry and Neuroscience Expert Dr. Joel Raskin Joins ArrivoBio as Chief Medical Advisor
Arrivo Bio Initiates Large Phase 2b Clinical Trial in Major Depressive Disorder with Novel SIRT6 Activator
Arrivo Announces FDA Fast Track Designation for RABI-767 for Patients with Acute Pancreatitis Predicted to Progress to Severe Disease
Arrivo BioVentures Begins Phase 1 Study of SP-624, the First Potential Treatment Specifically for Women with Major Depressive Disorder

News